ATRA
Atara Biotherapeutics Inc
NASDAQ: ATRA · HEALTHCARE · BIOTECHNOLOGY
$4.77
+3.70% today
Updated 2026-04-30
Market cap
$40.60M
P/E ratio
1.86
P/S ratio
0.34x
EPS (TTM)
$2.57
Dividend yield
—
52W range
$4 – $19
Volume
0.3M
Atara Biotherapeutics Inc (ATRA) Financial statements
SEC filings — annual and quarterly data.
Profit margin
27.10%
Operating margin
-339.60%
ROE
-2,015.00%
ROA
47.80%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | — | $-123.30M | — | — | — |
| 2013 | — | $-87.73M | — | — | — |
| 2014 | $0.00 | $-28.01M | — | — | — |
| 2015 | $0.00 | $-57.22M | — | — | — |
| 2016 | $0.00 | $-79.05M | — | — | — |
| 2017 | $0.00 | $-119.49M | — | — | — |
| 2018 | $0.00 | $-230.70M | — | — | — |
| 2019 | $0.00 | $-290.98M | — | — | — |
| 2020 | $3.55M | $-306.62M | -277.79% | -8,700.79% | -8,632.32% |
| 2021 | $20.34M | $-340.14M | 100.00% | -1,673.85% | -1,672.28% |
| 2022 | $63.57M | $-228.30M | 100.00% | -441.25% | -359.12% |
| 2023 | $8.57M | $-276.13M | -3.65% | -3,219.48% | -3,220.88% |
| 2024 | $128.94M | $-85.40M | 83.71% | -64.71% | -66.23% |
| 2025 | $120.77M | $32.69M | 82.44% | 29.69% | 27.07% |